Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
AUTOR(ES)
Simões, Belinda Pinto, Braga Junior, José Wilson Ramos, Rego, Maria Aparecida do Carmo, Souza, Cármino Antônio de
FONTE
Revista Brasileira de Hematologia e Hemoterapia
DATA DE PUBLICAÇÃO
2011-02
RESUMO
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
Documentos Relacionados
- Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
- Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
- Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
- Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
- Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
